Atossa Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Autifony Therapeutics Limited 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Ascletis Pharma Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

ASIT Biotech S.A. (ENXTBR:ASIT) 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Atara Biotherapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

ASLAN Pharmaceuticals Limited 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Assembly Biosciences, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Ascentage Pharma Group Corporation, Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Artios Pharma Limited 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Arsenal Biosciences, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Ascelia Pharma AB (publ) 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.

Arthex Biotech S.L. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.